埃森哲，投了一家AI制药_老虎社区_美港股上老虎

埃森哲，投了一家AI制药

智药局2025-12-12

近日，埃森哲宣布投资了Ryght AI，这是一家平台提供商，致力于现代化生命科学行业临床研究的设计和执行方式。该笔融资由埃森哲风险投资（Accenture Ventures）主导，将使生命科学和临床研究公司能够通过结合AI Agent与企业技术解决方案，更快地将新疗法带给患者。当前，临床试验流程日益复杂，导致严重延迟，尤其是在试验点选择和患者招募方面。随着新药开发成本的持续上升，人工选择部位可能...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2591463327?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-12 18:32","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2591463327","market":"us","top_or_hot":-1,"title":"埃森哲，投了一家AI制药","media":"智药局","content":"<div>\n<p>近日，埃森哲宣布投资了Ryght AI，这是一家平台提供商，致力于现代化生命科学行业临床研究的设计和执行方式。该笔融资由埃森哲风险投资（Accenture Ventures）主导，将使生命科学和临床研究公司能够通过结合AI Agent与企业技术解决方案，更快地将新疗法带给患者。当前，临床试验流程日益复杂，导致严重延迟，尤其是在试验点选择和患者招募方面。随着新药开发成本的持续上升，人工选择部位可能...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212195451a444d51d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>埃森哲，投了一家AI制药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n埃森哲，投了一家AI制药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-12 18:32 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212195451a444d51d&s=b><strong>智药局</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，埃森哲宣布投资了Ryght AI，这是一家平台提供商，致力于现代化生命科学行业临床研究的设计和执行方式。该笔融资由埃森哲风险投资（Accenture Ventures）主导，将使生命科学和临床研究公司能够通过结合AI Agent与企业技术解决方案，更快地将新疗法带给患者。当前，临床试验流程日益复杂，导致严重延迟，尤其是在试验点选择和患者招募方面。随着新药开发成本的持续上升，人工选择部位可能...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212195451a444d51d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739343.SGD","symbol_name":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212195451a444d51d&s=b","article_id":"2591463327","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212195451a444d51d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2591463327","pubTimestamp":1765535550,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，埃森哲宣布投资了Ryght AI，这是一家平台提供商，致力于现代化生命科学行业临床研究的设计和执行方式。该笔融资由埃森哲风险投资主导，将使生命科学和临床研究公司能够通过结合AI Agent与企业技术解决方案，更快地将新疗法带给患者。而此次投资与合作将结合埃森哲深厚的行业、技术和数据工程专长，与Ryght AI的AI平台，帮助生命科学公司加速药物开发中最关键的三个步骤：试验可行性、研究地点选择和患者招募。投资条款未予披露。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","ACN":"埃森哲","LU0323240290.USD":"HSBC GIF GLOBAL EQUITY CLIMATE CHANGE \"AD\" INC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0323239441.USD":"HSBC GIF GLOBAL EQUITY CLIMATE CHANGE \"AC\" ACC","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","BK4566":"资本集团","LU2247934214.USD":"FIDELITY FUNDS SUSTAINABLE FUTURE CONNECTIVITY \"A\" (USD) ACC","LU1046421795.USD":"富达环球科技A-ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1228905540.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC 2","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","BK4588":"碎股","LU1366333091.USD":"FIDELITY GLOBAL FOCUS \"A\" (USD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","BK4134":"信息科技咨询与其它服务","LU0545562505.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0157215616.USD":"FIDELITY GLOBAL FOCUS \"A\" INC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","BK4581":"高盛持仓","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","LU0149725797.USD":"汇丰美国股市经济规模基金","LU0342679015.USD":"ALLIANZ GLOBAL EQUITY UNCONSTRAINED \"AT\" (USD) ACC","IE00BHPRN162.USD":"BNY MELLON BLOCKCHAIN INNOVATION \"B\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","SG9999014906.USD":"大华全球优质成长基金Acc USD","BK4585":"ETF&股票定投概念"},"translate_title":"Accenture invested in an AI pharmaceutical","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACN":1.5},"content_text":"近日，埃森哲宣布投资了Ryght AI，这是一家平台提供商，致力于现代化生命科学行业临床研究的设计和执行方式。该笔融资由埃森哲风险投资（Accenture Ventures）主导，将使生命科学和临床研究公司能够通过结合AI Agent与企业技术解决方案，更快地将新疗法带给患者。当前，临床试验流程日益复杂，导致严重延迟，尤其是在试验点选择和患者招募方面。随着新药开发成本的持续上升，人工选择部位可能会为每项研究增加数周甚至数月的时间，造成重大瓶颈，拖慢整个开发过程，并阻碍许多有前景疗法的引入。Ryght AI通过其AI站点双生平台应对这些挑战，该平台创建临床研究场地的动态数字复制，实时捕捉历史表现、患者人口统计和运营数据。通过这些工具，使药企和CRO更容易识别最适合法规和协议的站点，更准确地预测注册情况，并简化站点激活工作流程。而此次投资与合作将结合埃森哲深厚的行业、技术和数据工程专长，与Ryght AI的AI平台，帮助生命科学公司加速药物开发中最关键的三个步骤：试验可行性、研究地点选择和患者招募。投资条款未予披露。此次投资是一系列创新生物技术初创企业投资的最新案例，包括1910 Genetics、Turbine和Earli，这些企业利用变革性技术加速临床试验和药物发现。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}